Nok Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-10-24.
Nok Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on October 24, 2025. The filing reports $649K sold. Its industry group is Biotechnology. It names Robert Lewis (No family relationship with Martin Lewis or Michael Lewis), Brian Cogley (Executive Officer, Director), Bruce Cassidy (Director) (SEC Form D/A, October 24, 2025).
Is this your company?
Sell to companies like Nok Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-24 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Nok Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Nok Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Pennsylvania, filed in October 2025, largest first.
Get an email when Nok Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Nok Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Nok Therapeutics, Inc. →Get the full cited report on Nok Therapeutics, Inc.
What the filing shows about Nok Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Nok Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Nok Therapeutics, Inc.'s address as 2009 Mackenzie Way, Suite 100, Cranberry Twp., PA 16066.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Nok Therapeutics, Inc. →
Amended on 2026-04-22: the amount sold changed from $566,500 to $649,000. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Nok Therapeutics, Inc. is a registered filer with the SEC (CIK 2038166) and has filed since 2025-10-24. 8 filings are on record, the latest on 2026-05-01.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Nok Therapeutics, Inc.'s Form D of 2025-10-24 names Robert Lewis, Brian Cogley, Bruce Cassidy and 3 more as its officers, directors or promoters.
Its new offerings report $818K sold across 3 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Parttime Salary of CEO, CFO, COO
On the filing as: Executive Officer, Director, Promoter.
Robert Lewis is named as No family relationship with Martin Lewis or Michael Lewis on the Form D that Nok Therapeutics, Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
Brian Cogley is named as Executive Officer and Director on the Form D that Nok Therapeutics, Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
Bruce Cassidy is named as Director on the Form D that Nok Therapeutics, Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
On the filing as: Director.
Martin Lewis is named as No family relationship with Michael Lewis or Robert Lewis on the Form D that Nok Therapeutics, Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
On the filing as: Promoter.
Michael Lewis is named as No family relationship with Martin Lewis or Robert Lewis on the Form D that Nok Therapeutics, Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
David Mehalick is named as Promoter on the Form D that Nok Therapeutics, Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role, 2 as directors only and 2 named in another capacity.
Named as of the 2025-10-24 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Nok Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Nok Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nok Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Nok Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Nok Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Nok Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/nok-therapeutics-inc-form-d-25000002